Literature DB >> 25518887

Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.

Michal Ząbczyk, Margareta Blombäck, Jacek Majewski, Grzegorz Karkowski, Hakan N Wallen, Anetta Undas, Shu He1.   

Abstract

Atrial fibrillation (AF) is a prothrombotic condition, involving increased thrombin generation and fibrinogen concentrations. Vitamin K antagonists (VKAs) prevent arterial thromboembolism if optimal anticoagulation is achieved by individualised drug doses, assessed by determining the Prothrombin time-related International Normalized Ratio (Pt-INR). There is evidence that formation of tight-laced fibrin networks is pathogenic in prothrombotic diseases. This study was performed among AF patients, to test whether long-term treatment with VKAs affects the structure of fibrin networks, and whether the effect is altered by employing different coagulation triggers: exogenous thrombin (1 IU/ml), 10 pM tissue factor (TF) or a commercial Pt-INR reagent (containing 400-fold more TF). In the thrombin-based method, fibrin network porosity (scanning electron microscopy) and liquid permeability (flow measurements) correlated inversely to fibrinogen concentrations, while positive correlations to the degree of anticoagulation were shown with the Pt-INR reagent. In the method with 10 pM TF, the two above relationships were detected, though the influence of Pt-INR was more profound than that of fibrinogen concentrations. Moreover, greater shortening of clot lysis time (CLT) arose from more permeable clots. As a coagulation trigger, 10 pM TF vs exogenous thrombin or the Pt-INR reagent is more informative in reflecting the in vivo process from thrombin generation to fibrin formation. Since fibrin network permeability rose in parallel to elevations of INR and shortening of CLT in AF patients, antithrombotic effects on prevention of thrombotic complications may be achieved from impairment of thrombin generation, resulting in formation of permeable clots susceptible to fibrinolysis.

Entities:  

Keywords:  Atrial fibrillation; Pt-INR; coagulation trigger; fibrin network permeability; vitamin K antagonists

Mesh:

Substances:

Year:  2014        PMID: 25518887     DOI: 10.1160/TH14-07-0591

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.

Authors:  Piotr Mazur; Jacek Myć; Joanna Natorska; Krzysztof Plens; Dariusz Plicner; Grzegorz Grudzień; Bogusław Kapelak; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

2.  Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Authors:  Oliver Königsbrügge; Günter Weigel; Peter Quehenberger; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2018-02-07       Impact factor: 3.984

Review 3.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

4.  An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC).

Authors:  S He; M Blombäck; F Boström; H Wallen; J Svensson; A Östlund
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

5.  Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism.

Authors:  Aneta Stachowicz; Michal Zabczyk; Joanna Natorska; Maciej Suski; Rafał Olszanecki; Ryszard Korbut; Jacek R Wiśniewski; Anetta Undas
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

6.  Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors.

Authors:  Julia S Gauer; Nicoletta Riva; Eden M Page; Helen Philippou; Michael Makris; Alex Gatt; Robert A S Ariëns
Journal:  Res Pract Thromb Haemost       Date:  2020-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.